IFEREX 150 (iron 150 mg) Dailymed
Generic: polysaccharide-iron complex is used for the treatment of Anemia, Hemolytic Anemia, Megaloblastic Hemochromatosis Hemosiderosis Pregnancy Complications, Hematologic Anemia, Iron-Deficiency
IMPRINT: ZIKS 0203 SHAPE: capsule
Go PRO for all pill images
Statement Of Identity
iFEREX 150 is an easily assimilated source of iron for treatment of uncomplicated iron deficiency anemia.
Healthn Claims
iFerex 150 is indicated for the prevention and treatment of iron deficiency anemia and/or nutritional megaloblastic anemias.
Warning
Accidental overdose of iron-containing products is a leading cause in fatal poisoning of children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately.
Dosage And Administration
Adults: One or two capsules daily or as directed by a physician.
Precautions
General: The type of anemia and underlying cause or causes should be determined before starting therapy with iFerex 150. Since the
anemia may be a result of systemic disturbance, such as recurrent blood loss, the underlying cause or causes should be corrected, if possible.
Safe Handling Warning
KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN.
DISPENSE IN A TIGHT, LIGHT-RESISTANT CONTAINER WITH A RESISTANT CLOSURE.
STORAGE: Store at 20oC-25​oC (68​o- 77oF); excursions to 15oC-30oC (59o-86oF)
Principal Display Panel - Iferex 150
ZIKs 63044-0203-01
iFEREX 150
Polysaccharide Iron
Complex Hematinic
100 Capsules
EACH CAPSULE CONTAINS:
Iron (elemental).....................150 mg
 (polysaccharide iron complex 326.1 mg)
INACTIVE INGREDIENTS: Black Iron oxide,FD&C Red #28, FD&C Yellow # 10, FD&C blue #1, FD&C red #40, FD&C yellow #6,gelatin, magnesium stearate, microcrystalline cellulose,Red Iron Oxide, and Titanium Dioxide
DESCRIPTION: iFerex 150 is a brown and orange capsule with marking "ziks 0203".
It is a product of ferric iron complexed to a low molecular weight polysaccharide.
INDICATIONS AND USAGE: iFerex 150 is indicated for the prevention and treatment of
iron deficiency anemia and/or nutritional megaloblastic anemias.
CONTRAINDICATIONS: iFerex 150 is indicated in patients with a known hypersensitivity
to any of the components of this product. Hemochromatosis and hemosiderosis are
contraindications to iron therapy.
ADVERSE REACTIONS: Adverse reactions with iron therapy may include constipation,
diarrhea, nausea, vomiting, dark stools, and abdomibal pain. Adverse reactions with iron
tharapy are usually transient.
WARNING: Accidental overdose of iron-containing products is a leading cause in
fatal poisoning of children under 6. Keep this product out of reach of children.
In case of accidental overdose, call a doctor or poison control center immediately.
PRECAUTIONS: General: The type of anemia and underlying cause or causes
should be determined before starting therapy with iFerex 150. Since the
anemia may be a result of systemic disturbance, such as recurrent blood loss,
the underlying cause or causes should be corrected, if possible.
DOSAGE AND ADMINISTRATION: Adults: One or two capsules daily or as directed by a physician.
KEEP THIS AND ALL DRUGS OUT OF REACH OF CHILDREN.
​DISPENSE IN A TIGHT, LIGHT-RESISTANT CONTAINER WITH A RESISTANT CLOSURE.
STORAGE: Store at 20​o​C-25​o​C (68​o​- 77​​o​F); excursions to 15​o​C-30​o​C (59​o-86​o​F)
HOW SUPPLIED: iFerex 150 capsules are supplied in 100 capsule per bottle.
Distributed by Nnodum Pharmaceuticals, Cincinnati, OH 45229
NP 6/18/09
LC-10872
3 63044 20301 2
reg
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
